{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-023762","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2025-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.605342+00:00","generated_at":"2026-05-24T21:39:35.578662+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cadrenal Therapeutics FY2024 net loss $10.7M; cash $10.0M; Abbott collaboration for Phase 3 tecarfarin trial","bullets":["Net loss of $10.7M for FY2024 (vs $8.4M in 2023); G&A expenses nearly doubled to $6.8M.","Cash and equivalents of $10.0M as of Dec 31, 2024, up from $8.4M year-end 2023; ~1.8M shares outstanding.","Collaboration with Abbott (NYSE: ABT) to support pivotal Phase 3 TECH-LVAD trial of tecarfarin.","FDA Type D meeting in Feb 2025 provided guidance for tecarfarin Phase 3 trial design; FDA requested full study synopsis.","Appointed Dr. James J. Ferguson as CMO and Jeff Cole as COO; received ODD for tecarfarin in LVAD patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-023762","json":"https://secwatch.observer/filing/0001213900-25-023762.json","markdown":"https://secwatch.observer/filing/0001213900-25-023762.md","text":"https://secwatch.observer/filing/0001213900-25-023762.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390025023762/0001213900-25-023762-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390025023762/ea023436601-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T21:39:35.578662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}